Pharmaceutical Technology·· 6 days agoPickScore56
China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
In brief
China's NMPA has approved the marketing application for Foresee Pharmaceuticals' Camcevi 42 mg for advanced prostate cancer in adults. The drug is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate. GenSci holds exclusive commercialization rights in China, covering central precocious puberty, premenopausal breast cancer, and advanced prostate cancer.
Why it matters
China's NMPA approved Camcevi 42 mg for adult advanced prostate cancer.
Source: Pharmaceutical Technology · pharmaceutical-technology.com